
KIN
Healthcare · Drug Manufacturers - Specialty & Generic · $420.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2021
EPS trend, 90 days to now · -6.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 5, 2021 | After the close | -0.18 | -0.20 | -8.5% |
| May 11, 2021 | After the close | -0.24 | -0.24 | -0.5% |
| Mar 16, 2021 | After the close | -0.28 | -0.28 | -1.2% |
| Nov 9, 2020 | After the close | -0.31 | -0.30 | +1.7% |
| Aug 5, 2020 | After the close | 0.15 | 0.66 | +323.8% |
| May 7, 2020 | After the close | -0.43 | -0.45 | -4.8% |
| Mar 16, 2020 | After the close | -0.40 | -0.40 | +0.4% |
| Nov 12, 2019 | After the close | -0.37 | -0.39 | -5.8% |
| Aug 1, 2019 | After the close | -0.38 | -0.37 | +3.4% |
| May 9, 2019 | After the close | -0.40 | -0.42 | -4.5% |
| Mar 6, 2019 | After the close | -0.46 | -0.46 | 0.0% |
| Nov 7, 2018 | After the close | -0.38 | -0.39 | -1.6% |
| Aug 9, 2018 | After the close | -0.39 | -0.39 |
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a…
| -0.5% |
| May 8, 2018 | After the close | -0.36 | -0.36 | -0.6% |
| Mar 1, 2018 | After the close | -0.31 | -0.35 | -13.6% |